Andecaliximab
- Generic Name
- Andecaliximab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1518996-49-0
- Unique Ingredient Identifier
- 571045EIM4
- Background
Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Ashibio Inc
- Target Recruit Count
- 92
- Registration Number
- NCT06508021
- Locations
- 🇺🇸
University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 144
- Registration Number
- NCT02864381
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 15
- Registration Number
- NCT02862574
- Locations
- 🇺🇸
Albuquerque Center for Rheumatology, Albuquerque, New Mexico, United States
🇺🇸Omega Research Consultants, LLC, DeBary, Florida, United States
🇺🇸Stanford University, Palo Alto, California, United States
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT02862535
Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 6
- Registration Number
- NCT02759562
Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 432
- Registration Number
- NCT02545504
- Locations
- 🇨🇱
Instituto Clinico Oncologico del Sur, Temuco, Chile
🇵🇪Centro Medico monte Carmelo, Arequipa, Peru
🇦🇺The Canberra Hospital, Garran, Australian Capital Territory, Australia
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 187
- Registration Number
- NCT02405442
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 11
- Registration Number
- NCT02077465
- Locations
- 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸University at Buffalo CTRC, Buffalo, New York, United States
🇺🇸Compass Research, LLC, Orlando, Florida, United States
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 74
- Registration Number
- NCT01831427
- Locations
- 🇺🇸
Ehrhardt Clinical Research, LLC, Belton, Missouri, United States
🇺🇸Delta Research Partners LLC, Monroe, Louisiana, United States
🇷🇴Institute of Pulmonology "Marius Nasta", Bucharest, Romania
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 236
- Registration Number
- NCT01803282
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸University of Southern California (USC), Los Angeles, California, United States
🇺🇸Parkview Research Center, Fort Wayne, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.